UK markets open in 21 minutes

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.7200+0.0700 (+1.92%)
At close: 04:00PM EDT
3.7500 +0.03 (+0.81%)
After hours: 07:06PM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees999

Key executives

NameTitlePayExercisedYear born
Dr. Alexander Zehnder M.B.A., M.D.CEO, MD & Member of Management Board1.07MN/A1970
Dr. Malte Greune Ph.D.COO, Member of Management Board & MD657.13kN/A1965
Dr. Myriam Mendila M.D.Chief Scientific Officer, Head of R&D, MD & Member of the Management Board672.17kN/A1966
Dr. Ulrike Gnad-Vogt M.D., Ph.D.Senior VP & Area Head of Oncology310.82kN/A1973
Dr. Sarah FakihVice President Corporate Communications & Investor RelationsN/AN/AN/A
Mr. Marco Rau L.L.M., Ph.D.General CounselN/AN/AN/A
Mr. Thorsten SchullerHead of Corporate CommunicationsN/AN/AN/A
Slavica Stevanovic-HeckHead of Human ResourcesN/AN/AN/A
Dr. Patrick BaumhofSenior Vice President of TechnologyN/AN/AN/A
Mr. Ronald PlasterkSenior Vice President of Science & InnovationN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.